GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » Degree of Financial Leverage

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Degree of Financial Leverage : 1.01 (As of Sep. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Eloxx Pharmaceuticals Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Eloxx Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Sep. 2023 was 1.01. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Eloxx Pharmaceuticals's Degree of Financial Leverage or its related term are showing as below:

ELOX's Degree of Financial Leverage is ranked worse than
54.77% of 1499 companies
in the Biotechnology industry
Industry Median: 0.97 vs ELOX: 1.01

Eloxx Pharmaceuticals Degree of Financial Leverage Historical Data

The historical data trend for Eloxx Pharmaceuticals's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eloxx Pharmaceuticals Degree of Financial Leverage Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 -0.86 1.10 0.18 1.23

Eloxx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.60 1.23 1.06 0.95 1.01

Competitive Comparison of Eloxx Pharmaceuticals's Degree of Financial Leverage

For the Biotechnology subindustry, Eloxx Pharmaceuticals's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eloxx Pharmaceuticals's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's Degree of Financial Leverage falls into.



Eloxx Pharmaceuticals Degree of Financial Leverage Calculation

Eloxx Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Sep. 2023 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -9.07 (Sep. 2023) / -19.33 (Sep. 2022) - 1 )/( -18.951 (Sep. 2023) / -40.033 (Sep. 2022) - 1 )
=-0.5308/-0.5266
=1.01***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Eloxx Pharmaceuticals  (OTCPK:ELOX) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Eloxx Pharmaceuticals Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Watertown, MA, USA, 02472
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Executives
Sumit Aggarwal director, officer: PRESIDENT AND CEO 480 ARSENAL WAY, WATERTOWN MA 02472
Vijay Modur officer: HEAD OF R&D C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451
Lindsay Androski director C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Gadi Veinrib director 12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Jasbir Seehra director C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Zafrira Avnur director 210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467
Alan Edmund Walts director 197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Pontifax Iv Gp L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax Management 4 G.p. (2015) Ltd. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (israel) Iv, L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (china) Iv L.p. 10 percent owner 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (cayman) Iv L.p. 10 percent owner 4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Headlines

From GuruFocus

Eloxx Pharmaceuticals Announces Reverse Stock Split Effective

By Value_Insider Value_Insider 12-01-2022